Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial
2006; Lippincott Williams & Wilkins; Volume: 67; Issue: 7 Linguagem: Inglês
10.1212/01.wnl.0000238518.34389.12
ISSN1526-632X
AutoresAndreas Bender, Walter Koch, Matthias Elstner, Y. Schombacher, Julia L. Glade Bender, M. Moeschl, Florian Gekeler, Bertram Müller‐Myhsok, Thomas Gasser, Klaus Tatsch, Thomas Klopstock,
Tópico(s)Transcranial Magnetic Stimulation Studies
ResumoMitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT.
Referência(s)